ALMR (Alamar Biosciences) Total Stockholders Equity: $-158.95 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALMR Alamar Biosciences Inc ALMR
8 GF Score
Price $24.85
! 1 Warning Sign
View Full Analysis

What is Alamar Biosciences Total Stockholders Equity?

Alamar Biosciences ALMR -2.13% 8 Total Stockholders Equity is $-158.95 Mil as of Dec. 2025. GuruFocus rates ALMR with a GF Score™ of 8/100. The stock has 1 warning sign investors should review.

Alamar Biosciences's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $-158.95 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Alamar Biosciences's Book Value per Share for the quarter that ended in Dec. 2025 was $-2.39. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Alamar Biosciences's Debt-to-Equity for the quarter that ended in Dec. 2025 was -0.26.

Alamar Biosciences  (NAS:ALMR) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Alamar Biosciences's Book Value per Share for the quarter that ended in Dec. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-158.954-0)/66.521
=-2.39

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Alamar Biosciences's Debt-to-Equity for the quarter that ended in Dec. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(2.099 + 39.374) / -158.954
=-0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alamar Biosciences Total Stockholders Equity Related Terms

Alamar Biosciences Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Alamar Biosciences's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alamar Biosciences Total Stockholders Equity Chart

Alamar Biosciences Annual Data
Trend Dec24 Dec25
Total Stockholders Equity
-133.41 -158.95

Alamar Biosciences Semi-Annual Data
Dec24 Dec25
Total Stockholders Equity -133.41 -158.95
ALMR
8GF Score
Alamar Biosciences Inc ALMR
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $-158.95 Mil mean?
Alamar Biosciences (ALMR) has a Total Stockholders Equity of $-158.95 Mil as of Dec. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Alamar Biosciences and its competitors.
Is Alamar Biosciences' Total Stockholders Equity too high?
Alamar Biosciences' current Total Stockholders Equity is $-158.95 Mil. Overall, Alamar Biosciences has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Alamar Biosciences' Total Stockholders Equity compare to UFPT and BFLY?
Alamar Biosciences' Total Stockholders Equity of $-158.95 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Medical Devices & Instruments company?
A good Total Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Alamar Biosciences and its competitors. Alamar Biosciences's current Total Stockholders Equity is $-158.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alamar Biosciences stock overvalued right now?
Alamar Biosciences (ALMR) has a current Total Stockholders Equity of $-158.95 Mil. The current Total Stockholders Equity is $-158.95 Mil. Alamar Biosciences' overall GF Score™ is 8/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Alamar Biosciences (ALMR), the current Total Stockholders Equity is $-158.95 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alamar Biosciences Business Description

Address 47071 Bayside Parkway, Fremont, CA, USA, 94538
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
8GF Score

Get the complete analysis for ALMR

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.85
Price